Young Manitobaans with cystic fibrosisnow have access to medications previously available to children 12 and older. The
state Wednesday announced it would extend eligibility for Trikafta, a drug used to treat cystic fibrosis, to her children aged 6 and older.
The change comes after Canada's Agency for Drugs and Technology last month recommended adjustments to make medicines more accessible to younger children.
READ MORE: Cystic Fibrosis Sufferer, Advocate Seeks Manitoba to Fund New 'Miracle' Drug
"Our government is committed to ensuring that the people of Manitoba have access to high-quality, innovative medicines that help them manage disease and significantly improve their quality of life." We are working to strengthen health care," said Health Minister Audrey Gordon.
"Trikafta has been shown to significantly improve the quality of life of people with cystic fibrosis, and we know this will give children and their families new hope." By expanding its reach to young people, we can ensure that they have access to this revolutionary drug so they can live their lives to the fullest for years to come." 22}
Story Continues Below Ad
Gordon encourages parents and caregivers who may benefit from trikafta to speak with their healthcare provider. rice field.
Read more: Cystic fibrosis remains the number one killer genetic disease for children in Canada. Here's why
Cystic Fibrosis Canada President and CEO Kelly Grover said this will change the future of many young children living with disabilities.
"Last year, Manitoba funded the drug for children aged 12 and over, and today, by extending the coverage of Tricapta to children aged 6 to 11,
"We celebrate this news with the CF community in Manitoba, who have worked tirelessly for this day."
© 2022 Global News, a division of Corus Entertainment Inc
